Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-707 vs pembrolizumab as first-line therapy in PD-L1 positive advanced NSCLC
CTR20251867Phase 3Active
- Sponsor
- Daniu Biotech
- Start
- May 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of PF-08634404 in non-small cell lung cancer (NSCLC), sponsored by Daniu Biotech. Started May 2025; status: active.
02
Drugs
PF-08634404
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20251867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251867.